Loading clinical trials...

NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts | Clinical Trials | Clareo Health

COMPLETED

NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts

NCT04960059•The Christie NHS Foundation Trust

Summary

This study will explore the ability of patients on first line combination immunotherapy to sample cytokines at home. The data from this study will be used to evaluate the feasibility of in-home testing and the ability to analyse patients cytokine profiles retrospectively to help feed the development of further studies.

Detailed Description

Patients will be informed of the study and given a minimum of 24 hours to consider. Once consented patients will enter the study where they will take cytokine samples at home over a 12 week period.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Voluntary informed consent.
•Aged at least 18 years.
•Diagnosis of locally advanced or metastatic RCC, Melanoma or NSCLC
•In the opinion of the investigator deemed suitable to receive first-line combination immunotherapy (RCC and MM) or combination immunotherapy and chemotherapy (NSCLC).
•Willingness to comply with scheduled trial procedures.
•Capable of performing own dry blood sampling procedure, or a carer who is willing and able to perform them.

Exclusion Criteria

•Previous immunotherapy (including any CPI either as single agent on in combination, or high dose interleukin-2).
•Judgement by the investigator that the individual should not participate if they are unlikely to comply with study procedures and requirements.
•Patients receiving long term oral anticoagulation deemed by the clinician to be at risk from daily finger pricking.

Locations (1)

The Christie NHS Foundation Trust

Manchester, United Kingdom

Key Dates

Start Date

February 11, 2022

Primary Completion Date

June 30, 2025

Completion Date

June 30, 2025

Last Updated

March 19, 2026

Enrollment

ACTUAL participants

Conditions

CancerMetastatic MelanomaRenal Cell CarcinomaNon-small Cell Lung Cancer

Interventions

No intervention

OTHER

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

RECRUITINGPHASE1

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 19, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts

Inclusion Criteria

Exclusion Criteria

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing